Valneva's Lyme Vaccine Clears the EMA's First Hurdle — While the Income Statement Still Has a Hill to Climb

Valneva shares rally on EMA's Lyme vaccine review, yet H1 revenue drops 33% and net loss widens to €63.3M, raising sustainability concerns.

The gap between what a stock price says and what a profit-and-loss statement reveals is rarely wider than it is at Valneva right now. The French vaccine developer has spent the past week riding a wave of regulatory optimism after European authorities accepted its Lyme disease candidate for formal review — even as the company's own half-year numbers show a business still shedding revenue and burning through cash.

A Regulatory Green Light With a Long Road Ahead

The European Medicines Agency validated the marketing application for VLA15 — also designated PF-07307405 — on 14 August, triggering a rally that at one point pushed the shares up by as much as 26 percent. Three days later, Pfizer and Valneva jointly confirmed that the EMA had begun its formal assessment of the hexavalent OspA-based vaccine, with a regulatory verdict expected within the next twelve months. Across the Atlantic, the US Food and Drug Administration is slated to weigh in during the second half of 2027.

That timeline matters. The market has already moved aggressively on the prospect of approval, not the reality of it. By the close of trading on 18 August, the stock was changing hands at €2.94, up roughly 20 percent over a seven-day stretch. One day earlier, it had touched €2.98 before giving back 2.6 percent — an early sign that some investors were locking in gains after the sharp run. Even after the surge, the shares remain in negative territory for the year to date.

The Numbers Tell a More Restrained Story

The euphoria around the EMA announcement sits awkwardly alongside the interim results Valneva published on 13 August — the day before the regulatory news broke. Total revenue for the first half came in at €65.8 million, a substantial drop from the €97.6 million recorded in the same period a year earlier. The net loss widened to €63.3 million, a shortfall the company attributed largely to the planned wind-down of third-party distribution agreements and one-off charges tied to its Chikungunya vaccine IXCHIQ.

Management has held firm on its full-year guidance, reiterating product sales of between €135 million and €150 million and total revenue of €145 million to €160 million for 2026. That implies a markedly stronger second half — a point that tends to get lost when the conversation is dominated by Lyme disease. Analysts' consensus for annual revenue sits at roughly €151.1 million, though that estimate predates the latest developments and should be treated as a rough benchmark at best.

To shore up its finances, Valneva has already taken the knife to its cost base. A global restructuring programme, including significant job cuts and a reprioritisation of research activities, is designed to reduce operational cash burn. The company ended June with €121.5 million in cash, bolstered by a reserved placement of €84 million led by Frazier Life Sciences and other healthcare investors earlier in the year. That provides breathing room, but it is not a substitute for a sustainable earnings base.

Side Bets and Sentiment Swings

Beyond the Lyme storyline, there are smaller catalysts percolating. Media reports suggest Valneva is close to securing a new contract with the US Department of Defense for its travel vaccine IXIARO — a deal that would bring steady, if modest, revenue. TD Cowen also initiated coverage on 14 August, explicitly identifying the Lyme programme as the central pillar of its investment thesis.

The market's reaction to the EMA news was nothing short of frenetic. Trading volume reportedly surged by more than 3,000 percent compared with the prior session, while sentiment on social media platforms flipped to "extremely bullish." For seasoned observers, such extremes are less a sign of fundamental conviction than a warning flag for short-term overheating.

A Stock With Two Stories

Valneva offers investors two narratives wrapped into a single equity. One is the regulatory dream: a potentially blockbuster Lyme vaccine developed alongside Pfizer, with a clear catalyst and a defined timeline. The other is the operational grind: falling revenue, mounting losses, and a workforce being trimmed to fit a leaner reality. The recent rally suggests the market is pricing the first story far more heavily than the second.

Whether that weighting is justified won't be known until the EMA actually delivers its verdict — and that remains months away. Until then, this is a stock trading on the outcome of an event that no one can reliably predict.